广谱氟喹诺酮类药物是否更易引发艰难梭菌相关性疾病？
Are broad-spectrum fluoroquinolones more likely to cause Clostridium difficile-associated disease?
作者信息
Dhalla Irfan A, Mamdani Muhammad M, Simor Andrew E, Kopp Alex, Rochon Paula A, Juurlink David N
机构信息
Department of Medicine, Unversity of Toronto, Ontario M4E 3E9, Canada.
出版信息
Antimicrob Agents Chemother. 2006 Sep;50(9):3216-9. doi: 10.1128/AAC.00592-06.
Abstract
Limited evidence suggests that broad-spectrum fluoroquinolones such as gatifloxacin and moxifloxacin are more likely to cause Clostridium difficile-associated disease than levofloxacin. In a population-based case-control study of outpatients prescribed fluoroquinolones, we found no increased risk of C. difficile-associated disease requiring hospitalization among patients prescribed gatifloxacin or moxifloxacin compared to levofloxacin.
摘要
有限的证据表明，加替沙星和莫西沙星等广谱氟喹诺酮类药物比左氧氟沙星更易引发艰难梭菌相关性疾病。在一项针对开具氟喹诺酮类药物门诊患者的基于人群的病例对照研究中，我们发现，与开具左氧氟沙星的患者相比，开具加替沙星或莫西沙星的患者中，因艰难梭菌相关性疾病而需住院治疗的风险并未增加。
相似文献
1
Are broad-spectrum fluoroquinolones more likely to cause Clostridium difficile-associated disease?
Antimicrob Agents Chemother. 2006 Sep;50(9):3216-9. doi: 10.1128/AAC.00592-06.
2
Molecular analysis of the gyrA and gyrB quinolone resistance-determining regions of fluoroquinolone-resistant Clostridium difficile mutants selected in vitro.
Antimicrob Agents Chemother. 2009 Jun;53(6):2463-8. doi: 10.1128/AAC.01252-08. Epub 2009 Apr 13.
3
Effects of exposure of Clostridium difficile PCR ribotypes 027 and 001 to fluoroquinolones in a human gut model.
Antimicrob Agents Chemother. 2009 Feb;53(2):412-20. doi: 10.1128/AAC.00306-08. Epub 2008 Aug 18.
4
Surface layer protein A variant of Clostridium difficile PCR-ribotype 027.
Emerg Infect Dis. 2011 Feb;17(2):317-9. doi: 10.3201/eid1702.100355.
5
In vivo selection of moxifloxacin-resistant Clostridium difficile.
Antimicrob Agents Chemother. 2012 May;56(5):2788-9. doi: 10.1128/AAC.06433-11. Epub 2012 Feb 27.
6
Elevated levels of intestinal inflammation in Clostridium difficile infection associated with fluoroquinolone-resistant C. difficile.
J Hosp Infect. 2009 Oct;73(2):185-7. doi: 10.1016/j.jhin.2009.05.013. Epub 2009 Aug 26.
7
In vitro activity of fluoroquinolones against common respiratory pathogens.
West Indian Med J. 2006 Jan;55(1):9-12. doi: 10.1590/s0043-31442006000100003.
8
Population pharmacokinetics of levofloxacin, gatifloxacin, and moxifloxacin in adults with pulmonary tuberculosis.
Antimicrob Agents Chemother. 2008 Mar;52(3):852-7. doi: 10.1128/AAC.01036-07. Epub 2007 Dec 10.
9
Evaluation of Clostridium difficile-associated diarrhea with a drug formulary change in preferred fluoroquinolones.
J Manag Care Pharm. 2008 Jan-Feb;14(1):34-40. doi: 10.18553/jmcp.2008.14.1.34.
10
Effects of subinhibitory concentrations of antibiotics on colonization factor expression by moxifloxacin-susceptible and moxifloxacin-resistant Clostridium difficile strains.
Antimicrob Agents Chemother. 2009 Dec;53(12):5155-62. doi: 10.1128/AAC.00532-09. Epub 2009 Oct 5.
引用本文的文献
1
Safety of fluoroquinolones.
Rev Esp Quimioter. 2024 Apr;37(2):127-133. doi: 10.37201/req/143.2023. Epub 2023 Dec 22.
2
Overview of Side-Effects of Antibacterial Fluoroquinolones: New Drugs versus Old Drugs, a Step Forward in the Safety Profile?
Pharmaceutics. 2023 Mar 1;15(3):804. doi: 10.3390/pharmaceutics15030804.
3
Antibiotic-Specific Risk for Community-Acquired Infection in the United States from 2008 to 2020.
Antimicrob Agents Chemother. 2022 Dec 20;66(12):e0112922. doi: 10.1128/aac.01129-22. Epub 2022 Nov 15.
4
Corticosteroids Do Not Increase the Likelihood of Primary Infection in the Setting of Broad-Spectrum Antibiotic Use.
Open Forum Infect Dis. 2021 Aug 11;8(10):ofab419. doi: 10.1093/ofid/ofab419. eCollection 2021 Oct.
5
Antibiotic Prescribing Choices and Their Comparative C. Difficile Infection Risks: A Longitudinal Case-Cohort Study.
Clin Infect Dis. 2021 Mar 1;72(5):836-844. doi: 10.1093/cid/ciaa124.
6
Fluoroquinolone-related adverse events resulting in health service use and costs: A systematic review.
PLoS One. 2019 Apr 26;14(4):e0216029. doi: 10.1371/journal.pone.0216029. eCollection 2019.
7
Meta-analysis of antibiotics and the risk of community-associated Clostridium difficile infection.
Antimicrob Agents Chemother. 2013 May;57(5):2326-32. doi: 10.1128/AAC.02176-12. Epub 2013 Mar 11.
8
Effects of ciprofloxacin on the expression and production of exotoxins by Clostridium difficile.
J Med Microbiol. 2013 May;62(Pt 5):741-747. doi: 10.1099/jmm.0.056218-0. Epub 2013 Feb 21.
9
Clostridium difficile-associated diarrhea in a tertiary care medical center.
Proc (Bayl Univ Med Cent). 2010 Oct;23(4):363-7. doi: 10.1080/08998280.2010.11928654.
10
Safety profile of the respiratory fluoroquinolone moxifloxacin: comparison with other fluoroquinolones and other antibacterial classes.
Drug Saf. 2009;32(5):359-78. doi: 10.2165/00002018-200932050-00001.
本文引用的文献
1
Moxifloxacin therapy as a risk factor for Clostridium difficile-associated disease during an outbreak: attempts to control a new epidemic strain.
Infect Control Hosp Epidemiol. 2007 Feb;28(2):198-201. doi: 10.1086/511789. Epub 2007 Jan 25.
2
Epidemic Clostridium difficile.
N Engl J Med. 2006 Mar 16;354(11):1199-203; author reply 1199-203.
3
Use of gastric acid-suppressive agents and the risk of community-acquired Clostridium difficile-associated disease.
JAMA. 2005 Dec 21;294(23):2989-95. doi: 10.1001/jama.294.23.2989.
4
An epidemic, toxin gene-variant strain of Clostridium difficile.
N Engl J Med. 2005 Dec 8;353(23):2433-41. doi: 10.1056/NEJMoa051590. Epub 2005 Dec 1.
5
A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality.
N Engl J Med. 2005 Dec 8;353(23):2442-9. doi: 10.1056/NEJMoa051639. Epub 2005 Dec 1.
6
Emergence of fluoroquinolones as the predominant risk factor for Clostridium difficile-associated diarrhea: a cohort study during an epidemic in Quebec.
Clin Infect Dis. 2005 Nov 1;41(9):1254-60. doi: 10.1086/496986. Epub 2005 Sep 20.
7
Appropriate outpatient treatment of acute bacterial exacerbations of chronic bronchitis.
Am J Med. 2005 Jul;118 Suppl 7A:39S-44S. doi: 10.1016/j.amjmed.2005.05.012.
8
New fluoroquinolones in lower respiratory tract infections and emerging patterns of pneumococcal resistance.
Infection. 2005 Jun;33(3):106-14. doi: 10.1007/s15010-005-4102-8.
9
A large outbreak of Clostridium difficile-associated disease with an unexpected proportion of deaths and colectomies at a teaching hospital following increased fluoroquinolone use.
Infect Control Hosp Epidemiol. 2005 Mar;26(3):273-80. doi: 10.1086/502539.
10
Fluoroquinolone prescribing in the United States: 1995 to 2002.
Am J Med. 2005 Mar;118(3):259-68. doi: 10.1016/j.amjmed.2004.09.015.
Zotero 插件